Home › T-Cell Lymphoma › Oregon › Portland
T-Cell Lymphoma clinical trials in Portland, OR
4 studies for T-Cell Lymphoma are looking for participants at sites in and around Portland (within about 30 miles). Open a study to see who can join and how to contact the study team.
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
RecruitingPhase 3
- Oregon Health & Science University; Knight Cancer Institute, Portland
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
RecruitingPhase 3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Providence Willamette Falls Medical Center, Oregon City · 12 mi away
MB-105 in Patients With CD5 Positive T-cell Lymphoma
RecruitingPhase 2
- Oregan Health & Science University, Portland
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RecruitingPhase 1
- Oregon Health & Science University, Portland
T-Cell Lymphoma trials in other cities
- New York City, NY13 studies
- Philadelphia, PA10 studies
- Baldwin Park, CA9 studies
- Boston, MA9 studies
- Houston, TX8 studies
- Atlanta, GA7 studies
- Seattle, WA6 studies
- Rochester, MN6 studies
- Columbus, OH6 studies
- Chicago, IL6 studies
- New Haven, CT5 studies
- Miami, FL5 studies
Other studies in Portland
- Non-Small Cell Lung Cancer45 studies
- Cancer (all types)35 studies
- Prostate Cancer33 studies
- Breast Cancer32 studies
- Metastatic Cancer30 studies
- Colorectal Cancer28 studies
- Ovarian Cancer27 studies
- Lung Cancer26 studies
- Endometrial Cancer25 studies
- Acute Myeloid Leukemia25 studies
- Head and Neck Squamous Cell Carcinoma19 studies
- Pancreatic Cancer19 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.